Lowenstein Sandler represented leading investment bank Piper Sandler (NYSE: PIPR) in its role as sole placement agent for the private placement of $100 million of common stock of Context Therapeutics Inc., a biopharmaceutical company advancing medicines for solid tumors.
The private placement was led by new investor Nextech, on behalf of one or more funds managed by it, with participation from new and existing investors, including Ally Bridge Group, Avidity Partners, Blackstone Multi-Asset Investing, Blue Owl Healthcare Opportunities, Deep Track Capital, Driehaus Capital Management, Great Point Partners, LLC, and other leading healthcare investors.
Piper Sandler Companies is a leading investment bank. Securities brokerage and investment banking services are offered in the U.S. through Piper Sandler & Co., member SIPC and NYSE; in the U.K. through Piper Sandler Ltd., authorized and regulated by the U.K. Financial Conduct Authority; and in Hong Kong through Piper Sandler Hong Kong Limited, authorized and regulated by the Securities and Futures Commission. Alternative asset management and fixed income advisory services are offered through separately registered advisory affiliates.
The Lowenstein deal team includes Steven M. Skolnick, Robert Paradiso, James C. Shehan, Stephen Zapf, and Erich J. Kaletka.
